People: Salix Pharmaceuticals Ltd (SLXP.O)
SLXP.O on Nasdaq
60.39USD
24 May 2013
60.39USD
24 May 2013
Price Change (% chg)
$0.70 (+1.17%)
$0.70 (+1.17%)
Prev Close
$59.69
$59.69
Open
$59.58
$59.58
Day's High
$60.85
$60.85
Day's Low
$59.50
$59.50
Volume
490,474
490,474
Avg. Vol
530,542
530,542
52-wk High
$60.85
$60.85
52-wk Low
$37.52
$37.52
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Thomas D'Alonzo |
66 | 2010 | Independent Chairman of the Board |
Carolyn Logan |
64 | 2002 | President, Chief Executive Officer, Director |
Adam Derbyshire |
47 | 2009 | Chief Financial Officer, Executive Vice President - Finance and Administration |
William Forbes |
51 | 2010 | Executive Vice President - Research and Development, CMO, Chief Development Officer |
Rick Scruggs |
53 | 2011 | Executive Vice President - Business Development |
John Chappell |
75 | 2010 | Independent Director |
William Keane |
57 | 2004 | Independent Director |
Mark Sirgo |
59 | 2008 | Independent Director |
G. Michael Freeman |
IR Contact Officer |
Biographies
| Name | Description |
|---|---|
Thomas D'Alonzo |
Mr. Thomas W. D'Alonzo is Independent Chairman of the Board of Salix Pharmaceuticals, Ltd. He has served as a member of Board of Directors since May 2000 and has been the Chairman of the Board since June 2010. Since 2005, Mr. D’Alonzo has served on the board of directors of Amarillo Biosciences, Inc., a public company, and Plexigen, Inc., a private company. From March 2007 to February 2009, Mr. D’Alonzo served as the Chief Executive Officer and a director of MiMedx Group, Inc. From May 2006 to April 2007, Mr. D’Alonzo was Chief Executive Officer of DARA BioSciences, Inc., now known as DARA Pharmaceuticals, Inc., and he served on its board of directors from September 2005 to December 2008. From 2000 to 2007, Mr. D’Alonzo acted as an independent consultant. Prior to that, from 1996 to 1999, Mr. D’Alonzo served as President and Chief Operating Officer of Pharmaceutical Product Development, Inc., or PPD, a global provider of discovery and development services to pharmaceutical and biotechnology companies. Before joining PPD, from 1993 to 1996, he served as President and Chief Executive Officer of GenVec, Inc., a clinical-stage, biopharmaceutical company. From 1983 to 1993, Mr. D’Alonzo held positions of increasing responsibility within Glaxo, Inc., the U.S. division of GSK, including President. Mr. D’Alonzo received his B.S. in Business Administration from the University of Delaware, and his J.D. from the University of Denver College of Law. |
Carolyn Logan |
Ms. Carolyn J. Logan is President, Chief Executive Officer, Director of Salix Pharmaceuticals, Ltd. She previously served as Senior Vice President, Sales and Marketing from June 2000 to July 2002. Prior to joining Salix, Ms. Logan served as Vice President, Sales and Marketing of the Oclassen Dermatologics Division of Watson Pharmaceuticals, Inc. from May 1997 to June 2000, and as its Vice President, Sales from February 1997 to May 1997. Prior to that date, she served as Director, Sales of Oclassen Pharmaceuticals, Inc. from January 1993 to February 1997. Prior to joining Oclassen, Ms. Logan held various sales and marketing positions with Galderma Laboratories, Ulmer Pharmacal and Westwood Pharmaceuticals, now known as Westwood-Squibb Pharmaceuticals, Inc., a subsidiary of Bristol-Myers Squibb. Ms. Logan received a B.S. degree in Biology and Dental Hygiene from the University of North Carolina at Chapel Hill. |
Adam Derbyshire |
Mr. Adam C. Derbyshire is Chief Financial Officer, Executive Vice President - Finance and Administration of Salix Pharmaceuticals, Ltd. Mr. Derbyshire previously served as Senior Vice President, Finance and Administration and Chief Financial Officer from June 2003 to January 2009 and as Vice President, Finance and Administration and Chief Financial Officer from June 2000 to June 2003. From June 1999 to June 2000, Mr. Derbyshire was Vice President, Corporate Controller and Secretary of Medco Research, Inc., acquired by King Pharmaceuticals, Inc. in February 2000, Corporate Controller and Secretary of Medco from September 1995 to June 1999 and Assistant Controller of Medco from October 1993 to September 1995. Mr. Derbyshire received his B.S. degree from the University of North Carolina at Wilmington and his MBA from the University of North Carolina at Charlotte. |
William Forbes |
Dr. William P. Forbes is Executive Vice President - Research and Development, Chief Medical Officer, Chief Development Officer of Salix Pharmaceuticals, Ltd. Dr. Forbes was Vice President, Clinical Development and Regulatory Affairs of Metabasis Therapeutics, Inc. He has also worked for Otsuka America Pharmaceutical, Inc. in a variety of roles of increasing responsibility from 1991 to 2002 and Glaxo, Inc. from 1989 through 1991. Dr. Forbes received his Doctor of Pharmacy degree from Creighton University. |
Rick Scruggs |
Mr. Rick D. Scruggs is Executive Vice President - Business Development of Salix Pharmaceuticals, Ltd. Mr. Scruggs previously served as Senior Vice President, Business Development from January 2009 to January 2011. Mr. Scruggs previously served as Vice President, Business Development from January 2006 to January 2009. From January 2004 to January 2006, Mr. Scruggs served as Vice President, Commercial Development. From 2000 to 2006, Mr. Scruggs was in various sales and commercial trade related positions at Salix. Before joining Salix, he served as Director of Managed Markets at Watson Pharmaceuticals, Inc., from May 1997 to July 2000. Prior to that, Mr. Scruggs served as Director, Managed Markets and Trade at Oclassen Pharmaceuticals, Inc., from January 1995 to February 1997. Before joining Oclassen, Mr. Scruggs held various sales and marketing positions of increasing responsibility with Johnson & Johnson and Ciba-Geigy. Mr. Scruggs received a B.S. degree in Criminal Justice from Appalachian State University. |
John Chappell |
Mr. John F. Chappell is Independent Director of Salix Pharmaceuticals, Ltd. He has served as a member of Board of Directors since December 1993 and was the Chairman of the Board from September 2003 until June 2010. From 1990 until his retirement in 2002, he served as founder and Chairman of Plexus Ventures LLC, a private company which specializes in business development and strategic transactions for clients in the biotechnology, pharmaceutical and drug delivery industries. Prior to founding Plexus Ventures LLC, Mr. Chappell served as Chairman, Worldwide Pharmaceuticals for SmithKline Beecham plc, now known as GlaxoSmithKline plc, or GSK, where he was responsible for the multi-billion dollar ethical pharmaceutical business with 30,000 employees worldwide. During his 28 years at SmithKline Beecham, Mr. Chappell also headed the International Consumer Products (OTC) operations and Corporate Planning & Development. He has served as a director of the Pharmaceutical Manufacturers Association, now known as PhRMA, and the Industrial Biotechnology Association, now known as BIO. Mr. Chappell holds a B.A. degree from Harvard University and attended the Wharton School of the University of Pennsylvania. |
William Keane |
Mr. William P. Keane is Independent Director of Salix Pharmaceuticals, Ltd since January 2004. From June 2007 to January 2010, Mr. Keane served on the board of directors of Intellect Neurosciences, Inc. From October 2002 until September 2005, Mr. Keane was the Chief Financial Officer and Corporate Secretary for Genta Incorporated, a biopharmaceutical company focused on the identification, development and commercialization of drugs for the treatment of patients with cancer. Prior to that, Mr. Keane was the Vice President-Sourcing, Strategy and Operations Effectiveness for Bristol-Myers Squibb Company from April 2001 until October 2002. From August 2000 until April 2001, Mr. Keane was the Chief Financial Officer for Covance Biotechnology Services, now known as Diosynth RTP Inc., a drug development services company. From September 1997 until July 2000, Mr. Keane was the Vice President, Finance – Global Pharmaceutical Manufacturing for Warner-Lambert Company, a pharmaceutical company subsequently acquired by Pfizer Inc. Mr. Keane received a B.A. in Microbiology and an M.B.A. from Rutgers University. |
Mark Sirgo |
Dr. Mark A. Sirgo is Independent Director of Salix Pharmaceuticals, Ltd since February 2008. Since July 2005, Dr. Sirgo has been the President and Chief Executive Officer of BioDelivery Sciences International, Inc., a specialty pharmaceutical company (Nasdaq:BDSI) , and has served in various executive positions at the company and as director of the company since August 2004. Prior to August 2004, Dr. Sirgo was the co-founder and Chief Executive Officer of Arius Pharmaceuticals, Inc., or Arius, which was acquired by BDSI in August 2004. Prior to his involvement with Arius, Dr. Sirgo spent three years as Senior Vice President of Global Sales and Marketing at Pharmaceutical Product Development, Inc. (Nasdaq:PPDI), and 16 years in a variety of positions of increasing responsibility in both clinical development and marketing at Glaxo, Glaxo Wellcome, and GSK, including Vice President of International OTC Development and Vice President of New Product Marketing. Dr. Sirgo received his B.S. in Pharmacy from The Ohio State University and his Doctorate from the Philadelphia College of Pharmacy and Science. |
G. Michael Freeman |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Thomas D'Alonzo |
-- |
Carolyn Logan |
5,027,040 |
Adam Derbyshire |
1,731,810 |
William Forbes |
1,576,070 |
Rick Scruggs |
1,104,330 |
John Chappell |
-- |
William Keane |
-- |
Mark Sirgo |
-- |
G. Michael Freeman |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Thomas D'Alonzo |
0 | 0 |
Carolyn Logan |
902,328 | 10,663,490 |
Adam Derbyshire |
563,128 | 6,592,529 |
William Forbes |
126,250 | 461,387 |
Rick Scruggs |
0 | 0 |
John Chappell |
0 | 0 |
William Keane |
0 | 0 |
Mark Sirgo |
0 | 0 |
G. Michael Freeman |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
SIRGO MARK A |
2,008 | $54.00 |
LOGAN CAROLYN J |
94,199 | $48.70 |
FORBES WILLIAM P |
23,741 | $48.70 |
SCRUGGS RICK D |
21,354 | $48.70 |
DERBYSHIRE ADAM C |
24,421 | $48.70 |
D ALONZO THOMAS WALTER |
4,110 | $48.70 |
KEANE WILLIAM P |
4,110 | $48.70 |
SIRGO MARK A |
4,110 | $48.70 |
CHAPPELL JOHN F |
4,110 | $48.70 |
KEANE WILLIAM P |
30,000 | $15.25 |
KEANE WILLIAM P |
30,000 | $49.44 |
FORBES WILLIAM P |
13,000 | $17.53 |
FORBES WILLIAM P |
8,673 | $49.37 |
D ALONZO THOMAS WALTER |
5,107 | $49.43 |
D ALONZO THOMAS WALTER |
15,000 | $7.60 |
D ALONZO THOMAS WALTER |
1,079 | $50.26 |
SIRGO MARK A |
3,000 | $50.05 |
SCRUGGS RICK D |
2,000 | $49.69 |
SCRUGGS RICK D |
5,000 | $49.34 |
SIRGO MARK A |
3,000 | $46.19 |
CHAPPELL JOHN F |
15,000 | $7.60 |
LOGAN CAROLYN J |
22,268 | $40.47 |
FORBES WILLIAM P |
5,052 | $40.47 |
DERBYSHIRE ADAM C |
6,130 | $40.47 |
SCRUGGS RICK D |
3,149 | $40.47 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
